GLP-1 weight loss claims on TikTok: sorting fact from hype

What did @drmiriamhere actually say?

The creator, who introduces herself as a medicine doctor, argues that Ozempic "is not a weight loss medication" because it cannot reach the 2.4 mg dose required to achieve the "14% promised weight loss" seen in clinical trials. She draws a contrast with Wegovy, which she says is "FDA approved for weight loss" and goes up to that higher dose. Her bottom line: providers who prescribe Ozempic off-label for weight loss are setting patients up for disappointment, not because the drug fails, but because the dose ceiling is too low.

The core argument is reasonable, but the way she frames it introduces some real problems, including a garbled drug name, an oversimplified dose-response claim, and a sign-off that borders on telling people not to trust medications at all.

Does the science back this up?

Partially, yes. The 2.4 mg distinction is real and well-supported. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) tested semaglutide 2.4 mg weekly in adults with obesity and found a mean weight reduction of about 14.9% over 68 weeks. Ozempic is approved at a maximum dose of 2 mg for type 2 diabetes. Wegovy uses the same molecule but at 2.4 mg, specifically studied and approved for chronic weight management.

However, the claim that you need exactly 2.4 mg to get meaningful weight loss is too rigid. A 2022 dose-finding analysis from the STEP program showed that lower doses of semaglutide still produced clinically significant weight loss, just less than at 2.4 mg. The 1 mg and 2 mg doses are not inert. Patients on Ozempic doses can and do lose meaningful weight, even if the average outcome is smaller than in the STEP 1 headline number.

What did they get wrong (or right)?

Let's start with what she got right. The regulatory distinction between Ozempic and Wegovy is accurate. They contain the same active ingredient, semaglutide, but are approved for different indications at different doses. Prescribing Ozempic off-label for weight loss, especially when Wegovy is available, deserves scrutiny. That point is fair.

What she got wrong, or at least badly muddled:

• She repeatedly mispronounces semaglutide as "semapholutotide" and Wegovy as "vagovii," which matters when you're presenting yourself as a clinical authority on a medication.
• The claim that you must reach 2.4 mg to get "the 14% promised weight loss" is misleading. The 14% figure is a trial average at that specific dose, not a guarantee. Individual outcomes vary considerably, and lower doses still produce real clinical benefit for many patients.
• Her closing line, "don't believe in medication," is vague enough to be genuinely harmful. Taken at face value, it undermines treatment adherence, which is a documented problem with GLP-1 therapy (Capehorn et al., 2022, Diabetes, Obesity and Metabolism).

What should you actually know?

If you are considering a GLP-1 medication for weight management, the dose and the approved indication both matter, but they are not the whole picture. Ozempic is not FDA-approved for weight loss, and that regulatory gap is clinically meaningful. Wegovy at 2.4 mg has the strongest evidence base specifically for weight management in people with obesity or overweight plus a weight-related condition.

That said, some patients do lose significant weight on Ozempic doses, and off-label use is legal and sometimes clinically appropriate. The bigger issue is informed consent: patients should know what dose they are on, what that dose is studied to achieve on average, and that individual results vary. A provider who prescribes Ozempic for weight loss without that conversation is skipping an important step, but the medication is not worthless below 2.4 mg.

Anyone making decisions about GLP-1 therapy should have that conversation with a licensed clinical provider who knows their full medical history, not based on a 60-second TikTok.